GRI

GRI Bio is a clinical-stage biopharmaceutical company developing novel therapeutic approaches for inflammatory, fibrotic, and autoimmune diseases. Its core product strategy centers on modulating Natural Killer T (NKT) cells, which are crucial regulators of the immune system's inflammatory cascade. The company's lead program, GRI-0621, targets and inhibits invariant NKT (iNKT) cell activity for idiopathic pulmonary fibrosis, while other pipeline assets are exploring diverse NKT cell agonists for conditions like systemic lupus erythematosus.

The company originated as Glycoregimmune, Inc. and was established in 2009, based in La Jolla, California. This founding marked an early focus on understanding and harnessing immune regulation, specifically the role of NKT cells, to address complex disease pathologies where inflammation and immune dysregulation are central. The early work aimed to develop innovative solutions beyond existing treatment paradigms for chronic debilitating conditions.

GRI Bio's therapies are intended for patients afflicted with severe inflammatory, fibrotic, and autoimmune disorders, offering new avenues for disease management. The company’s long-term vision involves fundamentally transforming treatment paradigms by interrupting disease progression and restoring immune homeostasis through precise NKT cell modulation. With a proprietary library of over 500 compounds, GRI Bio plans to continuously expand its pipeline to address significant unmet medical needs.